We are analyzing https://link.springer.com/article/10.1007/s11940-008-0007-z.

Title:
Neuromyelitis optica | Current Treatment Options in Neurology
Description:
Neuromyelitis optica (NMO, Devic’s syndrome) is characterized by concurrence of optic neuritis and transverse myelitis, typically associated with a lesion in the spinal cord extending over three or more vertebral segments. It is an inflammatory, demyelinating central nervous system disorder, and although it is most commonly relapsing, it is distinct from multiple sclerosis in that it is more severe, tends to spare the brain, and is associated with a longitudinally extensive lesion on spinal cord MRI. Furthermore, NMO is associated with a highly specific serum autoantibody marker, NMO-IgG, which targets the water channel aquaporin-4. The disease follows a relapsing course in more than 90% of patients. The relapses account for almost all disability associated with the disease because a secondary progressive course is uncommon, in contrast to multiple sclerosis. We recommend intravenous corticosteroids for acute myelitis and optic neuritis relapses, followed quickly by rescue plasmapheresis for severe, progressive, steroid-refractory events. Overwhelming evidence supports humoral autoimmune mechanisms in the pathogenesis of NMO, and most available data suggest that systemic immunosuppression is required to prevent attacks. We recommend long-term treatment with oral agents such as azathioprine or mycophenolate mofetil for patients with relatively mild disease and rituximab for those with more severe, recent attacks or treatment-refractory disease. We also recommend immunosuppression for at least 5 years in NMO-IgG seropositive patients presenting with a first-ever attack of longitudinally extensive transverse myelitis because they are at high risk for relapse or conversion to NMO.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, article, pubmed, neuromyelitis, optica, cas, neurology, multiple, sclerosis, treatment, neurol, wingerchuk, optic, disease, neuritis, weinshenker, patients, study, devics, brain, nmo, aquaporin, acute, lennon, severe, randomized, trial, privacy, cookies, content, relapses, lancet, pittock, lesions, data, publish, search, options, myelitis, spinal, cord, progressive, intravenous, corticosteroids, access, arch, clinical, mult, scler,

Topics {✒️}

month download article/chapter org/cmsc/images/pdf/ijmsc2000dec severe optic nerve high-dose intravenous immunoglobulin recommend long-term treatment mycophenolate mofetil placebo-controlled pilot study interferon beta-1b acute optic neuritis full article pdf nmo-igg-positive patients optic neuritis relapses serum autoantibody marker privacy choices/manage cookies severe optic neuritis open-label study multiple sclerosis lesions treatment-refractory disease progressive multiple sclerosis tarims study group side effects intravenous gamma globulin spinal cord extending spinal cord mri longitudinally extensive lesion neuromyelitis optica [abstract] recurrent neuromyelitis optica article wingerchuk optic neuritis european economic area recommend intravenous corticosteroids steroid-refractory events revised diagnostic criteria spinal cord lesions pattern-specific loss technology assessment subcommittee neuromyelitis optica treated water channel aquaporin-4 aquaporin-4 water channel conditions privacy policy anderson mm jr spinal cord demyelination check access anti-aquaporin 4 antibody instant access wingerchuk dm accepting optional cookies multiple sclerosis related subjects mandler rn

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Neuromyelitis optica
         description:Neuromyelitis optica (NMO, Devic’s syndrome) is characterized by concurrence of optic neuritis and transverse myelitis, typically associated with a lesion in the spinal cord extending over three or more vertebral segments. It is an inflammatory, demyelinating central nervous system disorder, and although it is most commonly relapsing, it is distinct from multiple sclerosis in that it is more severe, tends to spare the brain, and is associated with a longitudinally extensive lesion on spinal cord MRI. Furthermore, NMO is associated with a highly specific serum autoantibody marker, NMO-IgG, which targets the water channel aquaporin-4. The disease follows a relapsing course in more than 90% of patients. The relapses account for almost all disability associated with the disease because a secondary progressive course is uncommon, in contrast to multiple sclerosis. We recommend intravenous corticosteroids for acute myelitis and optic neuritis relapses, followed quickly by rescue plasmapheresis for severe, progressive, steroid-refractory events. Overwhelming evidence supports humoral autoimmune mechanisms in the pathogenesis of NMO, and most available data suggest that systemic immunosuppression is required to prevent attacks. We recommend long-term treatment with oral agents such as azathioprine or mycophenolate mofetil for patients with relatively mild disease and rituximab for those with more severe, recent attacks or treatment-refractory disease. We also recommend immunosuppression for at least 5 years in NMO-IgG seropositive patients presenting with a first-ever attack of longitudinally extensive transverse myelitis because they are at high risk for relapse or conversion to NMO.
         datePublished:2008-02-07T00:00:00Z
         dateModified:2008-02-07T00:00:00Z
         pageStart:55
         pageEnd:66
         sameAs:https://doi.org/10.1007/s11940-008-0007-z
         keywords:
            Multiple Sclerosis
            Mycophenolate Mofetil
            Optic Neuritis
            Main Side Effect
            Main Drug Interaction
            Neurology
            Intensive / Critical Care Medicine
            Internal Medicine
            Ophthalmology
            General Practice / Family Medicine
            Diabetes
         image:
         isPartOf:
            name:Current Treatment Options in Neurology
            issn:
               1534-3138
               1092-8480
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Science Inc.
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Dean M. Wingerchuk
               affiliation:
                     name:Mayo Clinic
                     address:
                        name:Department of Neurology, Mayo Clinic, Scottsdale, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Brian G. Weinshenker
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Neuromyelitis optica
      description:Neuromyelitis optica (NMO, Devic’s syndrome) is characterized by concurrence of optic neuritis and transverse myelitis, typically associated with a lesion in the spinal cord extending over three or more vertebral segments. It is an inflammatory, demyelinating central nervous system disorder, and although it is most commonly relapsing, it is distinct from multiple sclerosis in that it is more severe, tends to spare the brain, and is associated with a longitudinally extensive lesion on spinal cord MRI. Furthermore, NMO is associated with a highly specific serum autoantibody marker, NMO-IgG, which targets the water channel aquaporin-4. The disease follows a relapsing course in more than 90% of patients. The relapses account for almost all disability associated with the disease because a secondary progressive course is uncommon, in contrast to multiple sclerosis. We recommend intravenous corticosteroids for acute myelitis and optic neuritis relapses, followed quickly by rescue plasmapheresis for severe, progressive, steroid-refractory events. Overwhelming evidence supports humoral autoimmune mechanisms in the pathogenesis of NMO, and most available data suggest that systemic immunosuppression is required to prevent attacks. We recommend long-term treatment with oral agents such as azathioprine or mycophenolate mofetil for patients with relatively mild disease and rituximab for those with more severe, recent attacks or treatment-refractory disease. We also recommend immunosuppression for at least 5 years in NMO-IgG seropositive patients presenting with a first-ever attack of longitudinally extensive transverse myelitis because they are at high risk for relapse or conversion to NMO.
      datePublished:2008-02-07T00:00:00Z
      dateModified:2008-02-07T00:00:00Z
      pageStart:55
      pageEnd:66
      sameAs:https://doi.org/10.1007/s11940-008-0007-z
      keywords:
         Multiple Sclerosis
         Mycophenolate Mofetil
         Optic Neuritis
         Main Side Effect
         Main Drug Interaction
         Neurology
         Intensive / Critical Care Medicine
         Internal Medicine
         Ophthalmology
         General Practice / Family Medicine
         Diabetes
      image:
      isPartOf:
         name:Current Treatment Options in Neurology
         issn:
            1534-3138
            1092-8480
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Science Inc.
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Dean M. Wingerchuk
            affiliation:
                  name:Mayo Clinic
                  address:
                     name:Department of Neurology, Mayo Clinic, Scottsdale, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Brian G. Weinshenker
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Treatment Options in Neurology
      issn:
         1534-3138
         1092-8480
      volumeNumber:10
Organization:
      name:Current Science Inc.
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic
      address:
         name:Department of Neurology, Mayo Clinic, Scottsdale, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Dean M. Wingerchuk
      affiliation:
            name:Mayo Clinic
            address:
               name:Department of Neurology, Mayo Clinic, Scottsdale, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Brian G. Weinshenker
PostalAddress:
      name:Department of Neurology, Mayo Clinic, Scottsdale, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(133)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.59s.

LINK . SPRINGER . COM {}